Two other cases in ≥75 year-old females in Europe had received glimepiride for type 2 diabetes, a sulfonylurea drug associated with a haemolytic risk in G6PD-deficient patients and post-marketing reports of haemolytic anaemia in non-G6PD-deficient patients.41 Here, G6PD is linked to non-autoimmune hemolytic anemia.